Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02929329 · ClinicalTrials.gov registry record · Phase 3
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
A Phase 3 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,256
- Enrollment target
NCT02929329: Completed Phase 3 study, sponsored by Cytokinetics.
NCT02929329 is a Phase 3 study that has completed, run by Cytokinetics. The registered enrollment target is 8,256 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (971% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02929329, a Phase 3 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,256 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with omecamtiv mecarbil when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in adults with chronic heart failure with reduced ejection fraction (HFrEF).
Primary Outcome
The primary outcome was a composite of a heart-failure (HF) event or cardiovascular (CV) death, whichever occurred first, in a time-to-event analysis. A heart-failure event was defined as an urgent clinic visit, emergency department visit, or hospitalization for subjectively and objectively worsening heart failure leading to treatment intensification beyond a change in oral diuretic therapy. All deaths and HF events were adjudicated by an independent external clinical events committee (CEC) at
Interventions
- DRUG Placebo
- DRUG Standard of Care
- DRUG Omecamtiv Mecarbil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,256 participants |
| Start Date | 2017-01-06 |
| Est. Completion | 2020-09-14 |
| Phase | Phase 3 |
What the finished NCT02929329 record still lists
NCT02929329 is an interventional study that assigns participants to a tested intervention. Its 8,256 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (971% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02929329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02929329 about?
NCT02929329 is a clinical study titled "Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction". The purpose of this study is to determine if treatment with omecamtiv mecarbil when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in adults with chronic heart failure with reduced ejection fraction (HFrEF).
What is the current status of trial NCT02929329?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,256 participants. The study started on 2017-01-06. Estimated completion is 2020-09-14.
What interventions are being tested in trial NCT02929329?
The interventions under investigation include: Placebo (DRUG), Standard of Care (DRUG), Omecamtiv Mecarbil (DRUG).
Who is sponsoring clinical trial NCT02929329?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02929329's enrollment target sits among peer trials
8,256 32nd of 2000 higher than 1,969 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
- NCT06435806 · 8,200 participants · NA
Medical Illustration Design Characteristic Evaluation
- NCT06184945 · 8,100 participants · NA
Behavioral Economic & Staffing Strategies in the ICU
- NCT05593484 · 8,060 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI